SAB Biotherapeutics (SABS) Share-based Compensation (2021 - 2026)
SAB Biotherapeutics (SABS) posted Share-based Compensation of $97.4 million for Q1 2026, up 4898.72% on a QoQ basis from -$2.0 million in Q4 2025, and up 15790.34% year-over-year from N/an in Q1 2025.
SAB Biotherapeutics (SABS) Share-based Compensation (2021 - 2026) Analysis & Trends
SAB Biotherapeutics' Share-based Compensation history runs 6 years deep, the most recent figure standing at $97.4 million for Q1 2026.
- Quarterly Share-based Compensation rose 15790.34% year-over-year to $97.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $97.4 million (up 4973.78% YoY) and the FY2025 annual result came in at $38.0 million, up 503.17% from the prior year.
- Share-based Compensation was $97.4 million for Q1 2026 at SAB Biotherapeutics, up from -$2.0 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $97.4 million in Q1 2026 and bottomed at -$2.0 million in Q4 2025.
- A 5-year average of $6.0 million and a median of $578203.0 in 2022 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2025 — Share-based Compensation slumped 490.9% — and 2026, when it soared 15790.34%.
- SAB Biotherapeutics' Share-based Compensation stood at -$2.0 million in 2022, then jumped by 54.64% to -$893030.0 in 2023, then soared by 61.54% to -$343494.0 in 2024, then slumped by 490.9% to -$2.0 million in 2025, then soared by 4898.72% to $97.4 million in 2026.
- Business Quant data shows SABS's Share-based Compensation at $97.4 million in Q1 2026, -$2.0 million in Q4 2025, and $800764.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 9.26 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.18 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 87.30 Mn |
| 10 | SAB Biotherapeutics | 170.64 Mn | 170.64 Mn | - | 97.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 97.40 Mn |
| Mar 31, 2026 | 97.40 Mn |
| Dec 31, 2025 | -2.03 Mn |
| Dec 31, 2025 | -2.03 Mn |
| Sep 30, 2025 | 800,764.00 |
| Sep 30, 2025 | 800,764.00 |
| Jun 30, 2025 | 5.20 Mn |
| Jun 30, 2025 | 5.20 Mn |
| Mar 31, 2025 | 612,951.00 |
| Mar 31, 2025 | 612,951.00 |
| Dec 31, 2024 | -343,494.00 |
| Dec 31, 2024 | -343,494.00 |
| Sep 30, 2024 | 1.05 Mn |
| Sep 30, 2024 | 1.05 Mn |
| Jun 30, 2024 | 601,433.00 |
| Jun 30, 2024 | 601,433.00 |
| Mar 31, 2024 | 20,412.00 |
| Mar 31, 2024 | 20,412.00 |
| Dec 31, 2023 | -893,030.00 |
| Dec 31, 2023 | -893,030.00 |